An electrolyte including: a lithium salt, a non-aqueous solvent, an alkyl sulfonate compound represented by Formula 2, and an unsaturated sulfone compound represented by Formula 3:

##STR00001## wherein, in Formula 2, Q.sub.1 and Q.sub.2 are each independently a substituted or unsubstituted C.sub.1-C.sub.20 alkyl group, and in Formula 3, Q.sub.3 and Q.sub.4 are each independently a group represented by -(L.sub.1)-(R.sub.1), a vinyl group, an allyl group, or a substituted or unsubstituted C.sub.1-C.sub.20 alkyl group, and at least one of Q.sub.3 or Q.sub.4 is a group represented by -(L.sub.1)-(R.sub.1), a vinyl group, or an allyl group, Li is a substituted or unsubstituted C.sub.2-C.sub.20 alkenylene group or a substituted or unsubstituted C.sub.2-C.sub.20 alkynylene group, and Ri is hydrogen or a substituted or unsubstituted C.sub.2-C.sub.20 alkyl group.

Systems and processes for hydrotreating, splitting, and extracting a gasoil feed to produce a saturate-rich feedstock for olefin pyrolysis are provided. A gasoil feed is provided to a hydrotreating section to produce an ultralow sulfur distillate (ULSD) stream. The ULSD stream is provided to a splitter section to produce a light distillate stream and a heavy bottom stream. The light distillate stream is provided to an extraction section to produce an aromatic-rich extract phase and a saturate-rich raffinate phase. The raffinate phase is mixed with the heavy bottom stream to produce an olefin pyrolysis feedstock having a reduced BMCI as compared to the gasoil feed stream and the ULSD stream.

A novel onium salt having formula (1) and a resist composition comprising the same as a quencher are provided. When the resist composition is processed by photolithography using high-energy radiation, there is formed a resist pattern which is improved in LWR and CDU. In formula (1), R.sup.1, R.sup.2 and R.sup.3 each are a C.sub.1-C.sub.20 monovalent hydrocarbon group which may contain a heteroatom exclusive of fluorine, and Z.sup.+ is a sulfonium, iodonium or ammonium cation.

A secondary battery includes a positive electrode, a negative electrode, and an electrolytic solution where (A) the electrolytic solution contains a solvent and an electrolyte salt, the solvent containing ethylene carbonate, (B) a content of the electrolyte salt is from 0.8 mol/kg to 2.0 mol/kg both inclusive, (C) a content of the ethylene carbonate in the solvent is from 10 wt % to 30 wt % both inclusive, (D) a ratio M2/M1 of a number M2 of moles of the ethylene carbonate to a number M1 of moles of the electrolyte salt is from 0.4 to 2.4 both inclusive, and (E) the electrolytic solution contains at least one of sulfone compounds.

A secondary battery includes a positive electrode, a negative electrode, and an electrolytic solution where (A) the electrolytic solution contains a solvent and an electrolyte salt, the solvent containing ethylene carbonate, (B) a content of the electrolyte salt is from 0.8 mol/kg to 2.0 mol/kg both inclusive, (C) a content of the ethylene carbonate in the solvent is from 10 wt % to 30 wt % both inclusive, (D) a ratio M2/M1 of a number M2 of moles of the ethylene carbonate to a number M1 of moles of the electrolyte salt is from 0.4 to 2.4 both inclusive, and (E) the electrolytic solution contains at least one of sulfone compounds.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

Small molecule compounds derived from -sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.